CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse
Objective(s): Despite treatment with antibiotics and vaccination with BCG, tuberculosis (TB) is still considered as one of the most important public health problems in the world. Therefore, designing and producing a more effective vaccine against TB seems urgently. In this study, immunogenicity of a...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Mashhad University of Medical Sciences
2017-02-01
|
Series: | Iranian Journal of Basic Medical Sciences |
Subjects: | |
Online Access: | http://ijbms.mums.ac.ir/article_8231_564b4fba2fca6fd9f17d6ec263b8b059.pdf |
id |
doaj-f1dc9a57b69c49769f53a5be133a5e84 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ali Asghar Baghani Saman Soleimanpour Hadi Farsiani Arman Mosavat Masoud Yousefi Zahra Meshkat Seyed Abdolrahim Rezaee Saeid Amel Jamehdar Mohammad Reza Akbari Eydgahi Hamid Sadeghian Kiarash Ghazvini |
spellingShingle |
Ali Asghar Baghani Saman Soleimanpour Hadi Farsiani Arman Mosavat Masoud Yousefi Zahra Meshkat Seyed Abdolrahim Rezaee Saeid Amel Jamehdar Mohammad Reza Akbari Eydgahi Hamid Sadeghian Kiarash Ghazvini CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse Iranian Journal of Basic Medical Sciences CFP-10 Fcγ2a Immunogenicity Mycobacterium tuberculosis Subunit vaccine |
author_facet |
Ali Asghar Baghani Saman Soleimanpour Hadi Farsiani Arman Mosavat Masoud Yousefi Zahra Meshkat Seyed Abdolrahim Rezaee Saeid Amel Jamehdar Mohammad Reza Akbari Eydgahi Hamid Sadeghian Kiarash Ghazvini |
author_sort |
Ali Asghar Baghani |
title |
CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse |
title_short |
CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse |
title_full |
CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse |
title_fullStr |
CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse |
title_full_unstemmed |
CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse |
title_sort |
cfp10: mfcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse |
publisher |
Mashhad University of Medical Sciences |
series |
Iranian Journal of Basic Medical Sciences |
issn |
2008-3866 2008-3874 |
publishDate |
2017-02-01 |
description |
Objective(s): Despite treatment with antibiotics and vaccination with BCG, tuberculosis (TB) is still considered as one of the most important public health problems in the world. Therefore, designing and producing a more effective vaccine against TB seems urgently. In this study, immunogenicity of a fusion protein which consisting or comprising CFP-10 from Mycobacterium tuberculosis and the Fc-domain of mouse IgG2a was evaluated as a novel subunit vaccine candidate against TB. Materials and Methods: The genetic constructs were cloned in pPICZαA expression vector and recombinant vectors (pPICZαA-CFP-10: Fcγ2a and pPICZαA-CFP-10:His) were transformed into Pichia pastoris. To evaluate the expression of recombinant proteins, SDS-PAGE and immunoblotting were used. The immunogenicity of recombinant proteins, with and without BCG were assessed in BALB/c mice and specific cytokines against recombinant proteins (IFN-γ, IL-12, IL-4, IL-17 and TGF-β) were evaluated. Results: The levels of IFN-γ and IL-12 in mice that received recombinant proteins was higher than the control groups (BCG and PBS). Thus, both recombinant proteins (CFP-10:Fcγ2a and CFP-10:His) could excite good response in Th1-cells. The Fc-tagged protein had a stronger Th1 response with low levels of IL-4, as compared to CFP-10:His. However, the highest level of Th1 response was observed in groups that were vaccinated with BCG (prime) and then received recombinant protein CFP-10: Fcγ2a (booster). Conclusion: The results demonstrated that binding mice Fc-domain to CFP-10 protein can increase the immunogenicity of the subunit vaccine. Further studies, might be able to design and produce a new generation of subunit vaccines based on the Fc-fused immunogen. |
topic |
CFP-10 Fcγ2a Immunogenicity Mycobacterium tuberculosis Subunit vaccine |
url |
http://ijbms.mums.ac.ir/article_8231_564b4fba2fca6fd9f17d6ec263b8b059.pdf |
work_keys_str_mv |
AT aliasgharbaghani cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse AT samansoleimanpour cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse AT hadifarsiani cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse AT armanmosavat cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse AT masoudyousefi cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse AT zahrameshkat cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse AT seyedabdolrahimrezaee cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse AT saeidameljamehdar cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse AT mohammadrezaakbarieydgahi cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse AT hamidsadeghian cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse AT kiarashghazvini cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse |
_version_ |
1725434179122888704 |
spelling |
doaj-f1dc9a57b69c49769f53a5be133a5e842020-11-25T00:03:24ZengMashhad University of Medical SciencesIranian Journal of Basic Medical Sciences 2008-38662008-38742017-02-0120212213010.22038/ijbms.2017.82318231CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouseAli Asghar Baghani0Saman Soleimanpour1Hadi Farsiani2Arman Mosavat3Masoud Yousefi4Zahra Meshkat5Seyed Abdolrahim Rezaee6Saeid Amel Jamehdar7Mohammad Reza Akbari Eydgahi8Hamid Sadeghian9Kiarash Ghazvini10Antimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran|Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran|Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran|Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranHIV/AIDS, HTLV and Viral Hepatitis Research Center, Iranian Academic Center for Education, Culture and Research (ACECR), Mashhad, IranAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran|Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran|Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranImmunology Research Center, Inflammation and Inflammatory Diseases Division, Medical school, Mashhad University of Medical Sciences, Mashhad, IranAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran|Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranBiotechnology Research Center, Semnan University of Medical Sciences, Semnan, IranOrganic Chemistry, Department of Laboratory Sciences, Mashhad University of Medical Sciences, Mashhad, IranAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran|Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranObjective(s): Despite treatment with antibiotics and vaccination with BCG, tuberculosis (TB) is still considered as one of the most important public health problems in the world. Therefore, designing and producing a more effective vaccine against TB seems urgently. In this study, immunogenicity of a fusion protein which consisting or comprising CFP-10 from Mycobacterium tuberculosis and the Fc-domain of mouse IgG2a was evaluated as a novel subunit vaccine candidate against TB. Materials and Methods: The genetic constructs were cloned in pPICZαA expression vector and recombinant vectors (pPICZαA-CFP-10: Fcγ2a and pPICZαA-CFP-10:His) were transformed into Pichia pastoris. To evaluate the expression of recombinant proteins, SDS-PAGE and immunoblotting were used. The immunogenicity of recombinant proteins, with and without BCG were assessed in BALB/c mice and specific cytokines against recombinant proteins (IFN-γ, IL-12, IL-4, IL-17 and TGF-β) were evaluated. Results: The levels of IFN-γ and IL-12 in mice that received recombinant proteins was higher than the control groups (BCG and PBS). Thus, both recombinant proteins (CFP-10:Fcγ2a and CFP-10:His) could excite good response in Th1-cells. The Fc-tagged protein had a stronger Th1 response with low levels of IL-4, as compared to CFP-10:His. However, the highest level of Th1 response was observed in groups that were vaccinated with BCG (prime) and then received recombinant protein CFP-10: Fcγ2a (booster). Conclusion: The results demonstrated that binding mice Fc-domain to CFP-10 protein can increase the immunogenicity of the subunit vaccine. Further studies, might be able to design and produce a new generation of subunit vaccines based on the Fc-fused immunogen.http://ijbms.mums.ac.ir/article_8231_564b4fba2fca6fd9f17d6ec263b8b059.pdfCFP-10Fcγ2aImmunogenicityMycobacterium tuberculosisSubunit vaccine |